Key facts
- BioMosae’s last known valuation is $2.5M (Sep 2022).
- It has raised $3.7M; the latest was Later Stage VC ($4.1M) in Mar 2026.
- Notable investors include StartLife, Limburg Development and Investment Company.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BioMosae
- ·The full record, as it builds
Funding rounds
No funding rounds for BioMosae are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioMosae
Developer of metabolite-based biofungicides designed to control plant diseases through non-living microbial compounds. The company offers biofungicides derived from naturally occurring microbial metabolites with a distinct mode of action and consistent performance, enabling agricultural producers to manage crop diseases through sustainable and non-chemical approaches.
- Sector
- Healthcare
- HQ
- Geleen, Netherlands
- Founded
- 2018
- Employees
- 5
- Website
- biomosae.com/
- Ownership
- Privately Held (backing)
BioMosae doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioMosae shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioMosae in its N-PORT filings yet. We sweep new filings monthly.